8B2B5542-3E54-4643-BB57-0BEFCF89A16B
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 31.57030223390276
- age_years
- 44
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.485
- E2F_TARGETS+0.464
- MYC_TARGETS_V1+0.403
- MYC_TARGETS_V2+0.398
- MITOTIC_SPINDLE+0.357
- TGF_BETA_SIGNALING+0.316
- UNFOLDED_PROTEIN_RESPONSE+0.301
- NOTCH_SIGNALING+0.282
- DNA_REPAIR+0.273
- INTERFERON_ALPHA_RESPONSE+0.209
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.325
- KRAS_SIGNALING_DN-0.323
- MYOGENESIS-0.310
- ESTROGEN_RESPONSE_LATE-0.308
- SPERMATOGENESIS-0.284
- ANGIOGENESIS-0.276
- PANCREAS_BETA_CELLS-0.242
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.236
- XENOBIOTIC_METABOLISM-0.224
- COAGULATION-0.216
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934887 | — | — | 0.896 |
| 2 | D902E43A-F384-432A-B690-D20BFCC78443 | — | — | 0.895 |
| 3 | 1AF24109-5FE4-4868-ADB9-5DFDB57BCA0F | — | — | 0.891 |
| 4 | SRR934880 | — | — | 0.890 |
| 5 | A1E55AC6-A41F-454A-A3B6-8F49D2AAFEF2 | — | — | 0.887 |
| 6 | SRR934823 | — | — | 0.883 |
| 7 | SRR934847 | — | — | 0.882 |
| 8 | SRR934853 | — | — | 0.876 |
| 9 | 9F4AEC07-5C91-4009-BA26-E4947CAA3391 | — | — | 0.873 |
| 10 | 694B3BE3-104F-4D90-8733-4E99230EFAC6 | — | — | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.485 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.464 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.403 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.398 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.357 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.316 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.301 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.282 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.273 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.209 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.198 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.158 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.095 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.031 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.017 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.014 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.008 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.005 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.004 | Inavolisib | — uncovered |